Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: A randomized controlled trial

Clinical Infectious Diseases

Volumn 57, Issue SUPPL.2, 2013, Pages

  Hilsden, Robert J ^a   Macphail, Gisela ^b   Grebely, Jason ^c,d   Conway, Brian ^d,e   Lee, Samuel S ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Calgary Urban Project Society (CUPS) Health and Education Centres   (Canada)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Pender Community Health Centre   (Australia)

^e VANCOUVER INFECTIOUS DISEASES CENTRE   (Canada)

Author keywords

Directly observed therapy; Drug users; HCV; People who inject drugs

Indexed keywords

COCAINE; DIAMORPHINE; METHADONE; METHAMPHETAMINE; NARCOTIC AGENT; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFECTION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

DIRECTLY OBSERVED THERAPY; DRUG USERS; HCV; PEOPLE WHO INJECT DRUGS;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84881008980     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit327     Document Type: Article

References (32)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
2. Remis RS. Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada. Ottawa, ON: Public Health Agency of Canada, 2007.
3. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-73.
4. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2012; 56: 806-16.
5. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
7. Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012; 26: 359-75.
8. Iversen J, Grebely J, Topp L, et al. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011 [published online ahead of print 1 July 2013]. J Viral Hepat 2013; doi:10.1111/jvh.12129.
9. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-33.
10. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-8.
11. Grebely J, Tyndall MW. Management of HCV and HIV infections among people who inject drugs. Curr Opin HIVAIDS 2011; 6: 501-7.
12. Aspinall EJ, Corson S, Doyle JS, et al. Treatment of HCV infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57(Suppl 2):S80-9.
13. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
14. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
15. Marotta P, Hueppe D, Zehnter E, Kwo P, Jacobson I. Efficacy of chronic hepatitis C therapy in community-based trials. Clin Gastroenterol Hepatol 2009; 7:1028-36; quiz 2.
16. Lee SS, Sherman M, Ramji A, et al. Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3. Aliment Pharmacol Ther 2012; 35: 37-47.
17. Melin P, Chousterman M, Fontanges T, et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol 2010; 22: 1050-7.
18. Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat 2010; 38: 338-45.
19. Grebely J, Raffa JD, Meagher C, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007; 22: 1519-25.
20. Bruggmann P, Litwin AH. Models of care for the management of HCV among people who use drugs: one size does not fit all. Clin Infect Dis 2013; 57(Suppl 2):S56-61.
21. Lee SS, Roberts SK, Berak H, et al. Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients. Liver Int 2012; 32: 1270-7.
22. Grebely J, Matthews GV, Hellard M, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol 2011; 55: 76-85.
23. Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138:123-35 e1-2.
24. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29: 159-65.
25. Lindenburg CE, Lambers FA, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 23: 23-31.
26. Bruggmann P, Falcato L, Dober S, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat 2008; 15: 747-52.
27. Sasadeusz JJ, Dore G, Kronborg I, Barton D, Yoshihara M, Weltman M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction 2011; 106: 977-84.
28. Alavi M, Grebely J, Micallef M, et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opiate substitution setting: the ETHOS study. Clin Infect Dis 2013; 57(Suppl 2):S62-9.
29. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22: 270-7.
30. Grady B, Schinkel J, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 2013; 57(Suppl 2):S105-10.
31. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis 2011; 31: 331-9.
32. Myles A, Mugford GJ, Zhao J, Krahn M, Wang PP. Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol 2011; 25: 135-9.